Literature DB >> 19265088

Association between sputum atypia and lung cancer risk in an occupational cohort in Yunnan, China.

Ya-Guang Fan1, Ping Hu2, Yong Jiang3, Run-Sheng Chang4, Shu-Xiang Yao5, Wendy Wang6, Jie He7, Philip Prorok8, You-Lin Qiao3.   

Abstract

BACKGROUND: Individuals with cytologic atypia in sputum may be at high risk for the development of lung cancer.
METHODS: A prospective cohort study was conducted among occupational tin miners in Yunnan, China, based on an annual lung cancer screening program. Sputum samples were collected prospectively at baseline and the following seven annual screenings. The associations between risk factors and sputum cytology were analyzed by univariate and multivariate logistic regression. A proportional hazard model was used to analyze the association between the baseline sputum results and the incidence of lung cancer. The effect of consecutive sputum cytology on the increase of lung cancer risk was analyzed by logistic regression.
RESULTS: Sputum cytologic atypia was associated with age, smoking, occupational radon and arsenic exposure, and asthma. Sputum cytologic atypia was an independent risk factor for lung cancer with an adjusted hazard ratio (HR) of 3.82 (95% confidence interval [CI], 2.82 to 5.18) in comparing normal to moderate or worse atypia. Compared to the lung cancer risk associated with normal sputum, the risk was significantly higher according to the degree of atypia for squamous carcinomas, small cell lung cancer and central lung cancer, with adjusted HRs of 5.70 (95% CI, 3.78 to 8.59), 3.32 (95% CI, 1.31 to 8.45), and 4.93 (95% CI, 3.51 to 6.92), respectively.
CONCLUSIONS: Sputum atypia is associated with an increased risk of lung cancer. Sputum cytologic examination combined with other screening examinations may play an important role in the early detection of lung cancer or in the selection of the optimal target population for more intensive lung cancer screening among this occupational cohort or similar population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265088     DOI: 10.1378/chest.08-1469

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Lung cancer screening: an update, discussion, and look ahead.

Authors:  Peter J Mazzone
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

2.  Modification of association between prior lung disease and lung cancer by inhaled arsenic: A prospective occupational-based cohort study in Yunnan, China.

Authors:  Yaguang Fan; Yong Jiang; Ping Hu; Runsheng Chang; Shuxiang Yao; Bin Wang; Xuebing Li; Qinghua Zhou; Youlin Qiao
Journal:  J Expo Sci Environ Epidemiol       Date:  2016-04-13       Impact factor: 5.563

3.  Descriptive data on cancerous lung lesions detected by auto-fluorescence bronchoscope: A five-year study.

Authors:  Asmitananda Thakur; Lin Gao; Hui Ren; Tian Yang; Tianjun Chen; Mingwei Chen
Journal:  Ann Thorac Med       Date:  2012-01       Impact factor: 2.219

4.  [China National Lung Cancer Screening Guideline with Low-dose Computed 
Tomography (2018 version)].

Authors:  Qinghua Zhou; Yaguang Fan; Ying Wang; Youlin Qiao; Guiqi Wang; Yunchao Huang; Xinyun Wang; Ning Wu; Guozheng Zhang; Xiangpeng Zheng; Hong Bu; Yin Li; Sen Wei; Liang'an Chen; Chengping Hu; Yuankai Shi; Yan Sun
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-02-20

5.  Lung cancer risk following previous abnormal chest radiographs: A 27-year follow-up study of a Chinese lung screening cohort.

Authors:  Yaguang Fan; Zheng Su; Mengna Wei; Hao Liang; Yong Jiang; Xuebing Li; Zhaowei Meng; Ying Wang; Heng Wu; Jinzhao Song; Youlin Qiao; Qinghua Zhou
Journal:  Thorac Cancer       Date:  2021-11-09       Impact factor: 3.500

6.  China national lung cancer screening guideline with low-dose computed tomography (2015 version).

Authors:  Qing-Hua Zhou; Ya-Guang Fan; Hong Bu; Ying Wang; Ning Wu; Yun-Chao Huang; Guiqi Wang; Xin-Yun Wang; You-Lin Qiao
Journal:  Thorac Cancer       Date:  2015-08-04       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.